Mary Caffrey

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage cancer care over time.

Ted Okon, MBA, of the Community Oncology Alliance discusses how community oncology faces a revenue crisis due to the Inflation Reduction Act's impact on Medicare reimbursement, risking patient access to vital cancer treatments.

In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.

Coverage from IVBM Princeton, held May 8, 2025.

Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell transplant or CAR T-cell therapy.

New Jersey Attorney General Matthew Platkin said the question before the court is whether First Choice Women's Resource Centers can ignore a subpoena amid a state consumer fraud investigation.

A prior settlement of $6 billion was rejected because it would have shielded the Sackler family from lawsuits even from parties who were not part of the agreement.

A global surge in rheumatoid arthritis with local hotspots highlights the need for targeted public health interventions.

Dr Rugo discusses the promising outcomes of trastuzumab deruxtecan for HER2+ breast cancer, addressing interstitial lung disease risks and retreatment strategies.

A post-hoc analysis of EPCORE-NHL-1 was presented at ASCO.

Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center, discusses the potential consequences of losing free health care screening coverage.

Subcutaneous mosunetuzumab shows promising efficacy and safety in high-tumor burden follicular lymphoma, paving the way for outpatient treatment options.

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.

Rising early-onset colorectal cancer rates among young adults highlight the urgent need to explore lifestyle, genetics, and environmental factors driving this trend.

Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center, shares how one mobile health care initiative is addressing critical barriers to medical access for underserved populations.

Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.

Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; there is debate whether all newly diagnosed patients should have this regimen.

MATTERHORN shows durvalumab enhances survival in early-stage gastric and GEJ cancer, revolutionizing treatment approaches for patients.

Molecular testing identifies high-risk early-stage NSCLC patients for adjuvant chemotherapy, significantly improving disease-free survival rates post-surgery.

An ASCO session on quality services shows how patient and caregiver engagement is crucial to gain better outcomes and cost savings from symptom monitoring efforts.

Studies presented at ASCO reveal promising treatments for triple-negative and ER-positive breast cancer, highlighting the benefits of sacituzumab govitecan and vepdegestrant.

ASCO 2025 will showcase cutting-edge advancements in precision medicine, artificial intelligence, and biomarker-driven therapies, revolutionizing cancer treatment and diagnostics.

Following former President Joe Biden's diagnosis with metastatic prostate cancer, news coverage has focused on his lack of prostate-specific antigen (PSA) screening over the past decade.

Drugs first approved to treat diabetes, which later became a top sellers to aid weight loss, are associated with reduced risk of obesity-related cancer.

Assistance from artificial intelligence can potenially increase the number of patients eligible for treatment for HER2-low breast cancers.

ASCO and Google Cloud unveil an AI tool that streamlines access to clinical guidelines, enhancing decision-making for oncologists in patient care.

SCAN Group takes ownership of an integrated care delivery organization, to expand its impact on the lives of vulnerable seniors.

According to news reports, Biden's cancer is aggressive and has reached the bones.